专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

AU2020202182A1 Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses 未知
公开(公告)号：AU2020202182A1
公开(公告)日：2020-04-16
申请号：AU2020202182
申请日：2020-03-27
申请人： CELULARITY INC
发明人： GURNEY JODI P , ZHANG XIAOKUI , HERB STACY , HARIRI ROBERT J
IPC分类号： A61K45/00 , A01N63/00
摘要： Provided herein are compositions comprising mononuclear cells from human placental perfusate and methods of using such cells, including using the cells together with hematopoietic cells, for example to establish chimerism, reduce the severity or duration of graft versus host disease, treat or ameliorate symptoms of sarcopenia, metabolic disorders and hematologic disorders, such as hematologic malignancies, and treat or ameliorate symptoms of ischemic encephalopathy (e.g., hypoxic ischemic encephalopathy) and other central nervous system injuries.

2. 发明专利

AU2022215207A1 Therapy with cells from human placenta and hematopoietic cells 未知
公开(公告)号：AU2022215207A1
公开(公告)日：2022-09-01
申请号：AU2022215207
申请日：2022-08-10
申请人： CELULARITY INC
发明人： GURNEY JODI P , ZHANG XIAOKUI , HERB STACY , HARIRI ROBERT J
IPC分类号： A61K35/44
摘要： Provided herein are methods of treatment comprising administering to a subject, e.g., a human subject, mononuclear cells from human placental perfusate and hematopoietic cells, and compositions comprising them, and their uses to establish chimerism, engraft tissue (e.g., blood), reduce the severity or duration of graft versus host disease, and treat or ameliorate symptoms of metabolic disorders and hematologic disorders, such as hematologic malignancies.

3. 发明专利

AU2022215291A9 Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses 未知
公开(公告)号：AU2022215291A9
公开(公告)日：2022-11-24
申请号：AU2022215291
申请日：2022-08-12
申请人： CELULARITY INC
发明人： GURNEY JODI P , ZHANG XIAOKUI , HERB STACY , HARIRI ROBERT J
IPC分类号： A61K45/00 , A01N63/00
摘要： Provided herein are compositions comprising mononuclear cells from human placental perfusate and methods of using such cells, including using the cells together with hematopoietic cells, for example to establish chimerism, reduce the severity or duration of graft versus host disease, treat or ameliorate symptoms of sarcopenia, metabolic disorders and hematologic disorders, such as hematologic malignancies, and treat or ameliorate symptoms of ischemic encephalopathy (e.g., hypoxic ischemic encephalopathy) and other central nervous system injuries.

4. 发明专利

AU2014348454A1 Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses 未知
公开(公告)号：AU2014348454A1
公开(公告)日：2016-06-02
申请号：AU2014348454
申请日：2014-11-14
申请人： CELULARITY INC
发明人： GURNEY JODI P , ZHANG XIAOKUI , HERB STACY , HARIRI ROBERT J
IPC分类号： A61K45/00 , A01N63/00
摘要： Provided herein are compositions comprising mononuclear cells from human placental perfusate and methods of using such cells, including using the cells together with hematopoietic cells, for example to establish chimerism, reduce the severity or duration of graft versus host disease, treat or ameliorate symptoms of sarcopenia, metabolic disorders and hematologic disorders, such as hematologic malignancies, and treat or ameliorate symptoms of ischemic encephalopathy (e.g., hypoxic ischemic encephalopathy) and other central nervous system injuries.

5. 发明专利

AU2020202076A1 Therapy with cells from human placenta and hematopoietic cells 未知
公开(公告)号：AU2020202076A1
公开(公告)日：2020-04-09
申请号：AU2020202076
申请日：2020-03-23
申请人： CELULARITY INC
发明人： GURNEY JODI P , ZHANG XIAOKUI , HERB STACY , HARIRI ROBERT J
IPC分类号： A61K35/44
摘要： Provided herein are methods of treatment comprising administering to a subject, e.g., a human subject, mononuclear cells from human placental perfusate and hematopoietic cells, and compositions comprising them, and their uses to establish chimerism, engraft tissue (e.g., blood), reduce the severity or duration of graft versus host disease, and treat or ameliorate symptoms of metabolic disorders and hematologic disorders, such as hematologic malignancies.

6. 发明专利

AU2022215291A1 Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses 未知
公开(公告)号：AU2022215291A1
公开(公告)日：2022-09-01
申请号：AU2022215291
申请日：2022-08-12
申请人： CELULARITY INC
发明人： GURNEY JODI P , ZHANG XIAOKUI , HERB STACY , HARIRI ROBERT J
IPC分类号： A61K45/00 , A01N63/00
摘要： Title : Cardio Pulmonary Resuscitation Feedback System 5 A CPR feedback system (20) for assessing CPR carried out by a person on a subject and providing CPR feedback to the person, comprising an ECG system (22) configured to measure ECG signals of the subject, a biosignal system (24) configured to measure biosignals of the subject, a CPR assessment system (26) connected to the ECG system to receive ECG signals and connected to the biosignal system to receive biosignals, and a 10 CPR feedback unit (28) connected to the CPR assessment system and configured to receive CPR feedback signals and issue CPR feedback to the person, wherein the CPR assessment system is configured to perform the steps (i) establish a reference ECG signal metric and a target biosignal metric, (ii) produce a CPR feedback signal advising the person to start CPR, (iii) receive ECG signals measured during a plurality of chest 15 compressions and use the ECG signals to establish a current ECG signal metric, (iv) receive biosignals measured during the plurality of chest compressions and use the biosignals to establish a current biosignal metric, (v) compare the current ECG signal metric with the reference ECG signal metric and compare the current biosignal metric with the target biosignal metric, (vi) when the current ECG signal metric is less than the reference ECG 20 signal metric and the current biosignal metric is less than the target biosignal metric, produce a CPR feedback signal advising the person to improve CPR performance, (vii) when the current ECG signal metric is less than the reference ECG signal metric and the current biosignal metric is equal to or greater than the target biosignal metric, increase the target biosignal metric and produce a CPR feedback signal advising the person to 25 improve CPR performance, (viii) when the current ECG signal metric is equal to or greater than the reference ECG signal metric, set the reference ECG signal metric equal to the current ECG signal metric and produce a CPR feedback signal advising the person to maintain current CPR performance. 30 Figure 1 CPR FEEDBACK SYSTEM 20 22 BIOSIGNAL SYSTEM CPR ASSESSMENT CPRFEEDBACK Fig. 1

7. 发明专利

DK3052109T3 TERAPI MED CELLER FRA HUMAN PLACENTA OG HEMATOPOIETISKE CELLER 未知
公开(公告)号：DK3052109T3
公开(公告)日：2021-08-16
申请号：DK14850630
申请日：2014-10-02
申请人： CELULARITY INC
发明人： GURNEY JODI P , HERB STACY , ZHANG XIAOKUI , HARIRI ROBERT J
IPC分类号： A61K35/44 , A61K35/12 , A61K35/50 , A61K35/51 , A61P3/00 , A61P7/00 , A61P7/04 , A61P7/06 , A61P25/28 , A61P35/00 , A61P35/02 , A61P37/04 , A61P37/06 , A61P43/00

8. 发明专利

AU2014329513A1 Therapy with cells from human placenta and hematopoietic cells 未知
公开(公告)号：AU2014329513A1
公开(公告)日：2016-04-28
申请号：AU2014329513
申请日：2014-10-02
申请人： CELULARITY INC
发明人： GURNEY JODI P , ZHANG XIAOKUI , HERB STACY , HARIRI ROBERT J
IPC分类号： A61K35/44
摘要： Provided herein are methods of treatment comprising administering to a subject, e.g., a human subject, mononuclear cells from human placental perfusate and hematopoietic cells, and compositions comprising them, and their uses to establish chimerism, engraft tissue (e.g., blood), reduce the severity or duration of graft versus host disease, and treat or ameliorate symptoms of metabolic disorders and hematologic disorders, such as hematologic malignancies.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式